**Suppl 2. Demographical, clinical characteristics and outcomes of COVID-19 patients – with and without venous thromboembolism.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **No VTE** | **VTE** | **p-value** |
| **Total** | **4394** | **251** |  |
| Age, Median (IQR) \* | 66(52-77) | 64(52-75) | 0.81 |
| Male (%) | 51.9 | 61.4 | 0.003 |
| Race (%) \* |  |  | 0.08 |
| White | 71 | 67.7 |  |
| Blacks | 8.2 | 12.8 |  |
| Hispanic | 16.7 | 14.7 |  |
| Asian | 1.5 | 2.4 |  |
| Not disclosed | 2.7 | 2.4 |  |
| Blood group |  |  | 0.03 |
| A | 37.0 | 31.0 |  |
| B | 10.3 | 11.2 |  |
| AB | 2.5 | 7.1 |  |
| O | 49.2 | 50.8 |  |
| BMI | 30(25.7-35.6) | 31.3(26.5-37.5) | 0.81 |
| Co-morbidities (%) |  |  |  |
| Hypertension | 71.7 | 73.3 | 0.57 |
| Congestive Heart Failure | 29.4 | 33.5 | 0.17 |
| Diabetes Mellitus | 44 | 47.4 | 0.28 |
| Chronic Obstructive Pulmonary Disease | 35.7 | 29.4 | 0.22 |
| End Stage Renal Disease | 3.5 | 4.8 | 0.28 |
| Cirrhosis | 12.4 | 13.2 | 0.72 |
| Cancer | 13.1 | 11.6 | 0.47 |
| History of VTE | 5.6 | 10.0 | 0.004 |
| Home meds (%) |  |  |  |
| Anticoagulation | 12.1 | 6.8 | 0.01 |
| NSAIDs | 17.3 | 15.1 | 0.38 |
| P2Y12 inhibitors | 5.4 | 5.2 | 0.87 |
| Statins | 29.9 | 28.7 | 0.67 |
|  |  |  |  |
|  |  |  |  |
| COVID-19 Medications (%) |  |  |  |
| Vitamin C | 80.5 | 92.0 | <0.001 |
| Thiamine | 6.6 | 9.6 | 0.07 |
| Zinc | 79.8 | 91.2 | <0.001 |
| Hydroxychloroquine | 5.3 | 9.6 | 0.004 |
| Tocilizumab | 5.6 | 14.3 | <0.001 |
| Steroids | 66.5 | 47.0 | <0.001 |
| Convalescent plasma | 25.1 | 39.8 | <0.001 |
| Remedesivir | 57.1 | 61.7 | 0.017 |
| Ivermectin | 3.9 | 8.8 | <0.001 |
| Anticoagulation |  |  | <0.001 |
| None | 10.9 | 47.8 |  |
| Standard | 72.1 | 41.0 |  |
| High  |  |  |  |
| Intermediate | 1.3 | 1.2 |  |
| Therapeutic | 15.8 | 10.0 |  |
| Other |  |  |  |
| Acute stroke | 2.3 | 4.8 | 0.016 |
| Acute intracranial bleeding | 1.2 | 3.2 | 0.005 |
| Atrial fibrillation | 17.2 | 13.6 | 0.13 |
| Acute Kidney Injury | 15.4 | 30.3 | 0.001 |
| Acute renal failure requiring hemodialysis | 2.3 | 9.6 | 0.001 |
|  |  |  |  |
| Died (%) | 15.0 | 28.7 | <0.001 |
| LOS1 in survivors, median (IQR) | 5(3-8) | 8(4-27) | <0.001 |
| Time to death, median (IQR) | 10(5-18) | 14.5(9-24) | <0.001 |
| Disposition (%) |  |  | <0.001 |
| Home | 65.7 | 44.1 |  |
| Home with health | 17.6 | 22.4 |  |
| SNF/LTAC/Rehab2 | 12.5 | 24.0 |  |
| Others | 4.1 | 9.5 |  |
| Readmissions | 13.5 | 11.2 | 0.37 |